A Agilent Technologies Inc.

Agilent Unveils the 8850 Gas Chromatograph: A Leap Forward in Analytical Excellence

, (NYSE: A) proudly announces the , a small single-channel GC that combines the legacy of the 6850 GC with the capability and system intelligence of the 8890 GC. With a focus on speed and intelligence, the 8850 GC stands poised to revolutionize labs across diverse markets, including energy, chemicals, food, and pharmaceuticals, while reducing energy consumption by up to 30%.

Modern labs face the seemingly contrasting goals of maximizing analytical capacity with limited bench space while reducing the overall environmental impact of their operations. In response, lab managers strive to get the most productivity out of every square foot of their facility by maximizing instrument uptime and ensuring optimal use of all available bench space. Meeting sustainability goals amid these pressures requires an unwavering focus on the efficiency of lab operations and individual workflow components.

“We are excited to introduce the 8850 GC, a cutting-edge instrument that leverages the latest technological advancements,” stated Mike Zhang, vice president and general manager of the Gas Phase Separations Division at Agilent. “Incorporating engineering excellence and the intelligence of Agilent’s smart GC portfolio, this compact, rugged GC is poised to revolutionize analytical labs across various industries. It delivers answers quickly and efficiently while significantly reducing physical space and energy requirements.”

Integrated instrument intelligence enhances uptime, while remote connectivity features facilitate regular maintenance and troubleshooting, ensuring uninterrupted workflow capacity. The instrument’s small footprint – half the size of the Agilent 8890 GC – maximizes space utilization and operational redundancy. Additionally, heating and cool-down times are shorter, increasing lab throughput. Using up to 30% less power than other GCs reduces energy costs and helps labs meet their sustainability goals.

“The 8850 GC speaks directly to labs’ goals as a small, dedicated single-channel GC with the power of instrument intelligence and the high-end performance of the 8890 GC,” added Jim Gearing, associate vice president of Marketing, in the Gas Phase Separations Division at Agilent. “For ease of use, the 8850 GC uses the same touchscreen interface and connectivity as the 8890 GC, and method migration and development efforts are minimized due to familiar consumables and software, enabling a straightforward transition to the 8850 GC.”

The 8850 GC is a powerful addition to Agilent’s market-leading portfolio of GC instruments. Learn more by registering to join this live event, . With its small footprint and user-friendly interface, this instrument combines reliability, dedicated high performance, and exceptional data quality, promising to transform lab operations.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the . Follow Agilent on and .

EN
23/05/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch